血清中microRNA在预测肝细胞癌患者预后作用的研究探讨

doi:10.11904/j.issn.1002-3070.2016.02.010

Abstract

Abstract: Hepatocellular carcinoma(HCC)is one of the most malignant tumors,transcatheter arterial chemoembolization(TACE)is a new treatment for HCC,which is currently considered as the standard care for patients with unresectable HCC.MicroRNAs(miRNAs),a class of small non-coding RNAs,the correlations within miRNA dictions and tumor prognosis have been documented,and a part of miRNAs has been proposed as biomarkers to reliably predict the outcomes before HCC patients being treated with TACE.

Key words: HCC, miRNA, TACE, Prognosis, Biomarker

CLC Number:

R735.7

WANG Ye, CHANG Zhihui, ZHAO Xiangxuan, LIU Zhaoyu. The prognosis predicting effect of serum microRNA in the patients with hepatocellular carcinoma[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 142-145.

References

1 Yang JD,Roberts LR.Epidemiology and management of hepatocellular carcinoma[J].Infect Dis Clin North Am,2010,24(4):899-919.
2 Lee JO,Lee KW,Oh DY,et al.Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma[J].Ann Oncol,2009,20(8):1402-1407.
3 Cui LM,Hu Y,Bai B,et al.Serum miR-335 level is associated prognosis in patients with hepatocellular carcinoma[J].Cell Physiol Biochem,2015,37(1):276-283.
4 He L,Hannon GJ.MicroRNAs:small RNAs with a big role in gene regulation[J].Nat Rev Genet,2004,5(7):522-531.
5 Esteller.Non-coding RNAs in human disease[J].Nat Rev Genet,2011,12(12):861-874.
6 Ling H,Fabbri M,Calin GA.et al.MicroRNAs and other non-coding RNAs as targets for anticancer drug development[J].Nat Rev Drug Discov,2013,12(11):847-865.
7 Ueda T,Volinia S,Okumura H,et al.Relation between microRNA expression and progression and prognosis of gastric cancer:a microRNA expression analysis[J].Lancet Oncol,2010,11(2):136-146.
8 Zhou J,Yu L,Gao X,et al.Plasma microrna panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J].J Clin Oncol,2011,29(36):4781-4788.
9 Cho HJ,Kim JK,Nam JS,et al.High circulating microRNA-122 expression is a poor prognostic marker in patients with hepatitis B virus related hepatocellular carcinoma who undergoing radiofrequency ablation[J].Clin Biochem,2015,48(16-17):1073-1078.
10 Chen L,Chu FH,Cao YL,et al.Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma[J].Tumor Biol,2015,36(10):7439-7447.
11 Wang Y,Toh HC,Chow P,et al.MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms[J].FASEB J,2012,26(7):3032-3041.
12 Zhuang LP,Meng ZQ.Serum miR-224 reflects stage of hepatocellular carcinoma and predicts survival[J].Bio Med Res Int,2015,2015:731781.
13 Selcuklu SD,Donoghue MA,Spillane C,et al.MiR-21 as a key regulator of oncogenic processes[J].Biochem Soc T,2009,37(Pt 4):918-925.
14 Zhu S,Wu H,Wu F,et al.MicroRNA-21 targets tumor suppressor genes in invasion and metastasis[J].Cell Res,2008,18(3):350-359.
15 Qian B,Katsaros D,Lu L,et al.High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1[J].Breast Cancer Res Tr,2009,117(1):131-140.
16 Gao W,Shen H,Liu L,et al.MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis[J].J Cancer Res Clin,2011,137(4):557-566.
17 Dillhoff M,Liu J,Frankel W,et al.MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival[J].J Gastrointest Surg,2008,12(12):2171-2176.
18 Ying Q,Liang L,Guo W,et al.Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein inhepatocellular carcinoma[J].Hepatology,2011,54(6):2064-2075.
19 Zhan MX,Li Y,Hu BS,et al.Serum MicroRNA-210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization[J].Lab Invest,2014,25(8):1279-1287.
20 Hung CS,Liu HH,Liu JJ,et al.MicroRNA-200a and-200b mediated hepatocellular carcinoma cell migration through the epithelial to mesenchymal transitionmarkers[J].Ann Surg oncol,2013,20(3):360-368.
21 Dhayat SA,Mardin WA,Kohler G,et al.The microRNA-200 family-A potential diagnostic marker in hepatocellular carcinoma[J].J Surg Oncol,2014,110(4):430-438.
22 Liu M,Liu J,Wang L,et al.Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival[J].PLoS One,2014,9(10):e109347.
23 Zhang J,Tu Q,Bonewald LF,et al.Effects of miR-335-5p in modulating osteogenic differentiation by specifically downregulating Wnt antagonist DKK1[J].J Bone Miner Res,2011,26(8):1953-1963.
24 Cao J,Cai J,Huang D,et al.miR-335 represents an invasion suppressor gene in ovarian cancer by targeting Bcl-w[J].Oncol Rep,2013,30(2):701-706.
25 Peng HH,Zhang YD,Gong LS,et al.Increased expression of microRNA-335 predicts a favorable prognosis in primary gallbladder carcinoma[J].Onco Targets Ther,2013,6(5):1625-1630.
26 Zheng J,Lin Z,Dong P,et al.Activation of hepatic stellate cells is suppressed by microRNA-150[J].Int J Mol Med,2013,32(1):17-24.
27 Zhang J,Luo N,Luo Y,et al.microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb[J].Int J Oncol,2012,40(40):747-756.
28 Yu FJ,Lu ZQ,Chen BC,et al.microRNA-150:a promising novel biomarker for hepatitis B virus-related hepatocellular carcinoma[J].Diagn Pathol,2015,10(1):129-138.
29 Tian S,Huang S,Wu S,et al.MicroRNA-1285 inhibits the expression of p53 by directly targeting its 3′ untranslated region[J].Biochem Biophys Res Commun,2010,396(2):435-439.
30 Liu JB,Yan JC,Zhou CC,et al.miR-1285-3p acts as a potential tumor suppressor miRNA via downregulating JUN expression in hepatocellular carcinoma[J].Tumor Biol,2015,36(8):219-225.

[1]	ZHANG Jiawen,YU Yan,ZHANG Wei,CAO Jingyan,LUO Wen,SHANG Lihua. Serum metabolomics of small cell lung cancer patients based on UPLC-TOF/MS [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 200-205.
[2]	WANG Xiaoya,XIAO Bin,LIAO Yang,TANG Rongzhi,SUN Zhaohui,LI Linhai. Expression of CXCR family proteins in different subtypes of breast cancer and their clinical prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 206-210.
[3]	FENG Yue,XING Linan,WANG Zhao,ZHANG Yunyan. Correlation between NLR and prognosis of concurrent chemoradiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 284-288.
[4]	LV Bowen, QIAN Jun, WANG Jie, QIAN Jingrong, LU Yingying, SU Liju, YANG Tongshu, LI Wenhui. Expression of MiR-455-5p in epithelial ovarian cancer and its target gene function [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 115-121.
[5]	BAI Xiaobin, HUO Longwei, XIE Wanfu, XU Gaofeng, WANG Maode. Expression of Chk1 in glioblastoma and its association with tumor biological behavior and prognosis survival [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 122-127.
[6]	SHI Xiaokang, DING Youming, WANG Bin, YU Bin, XU Yu. Expression and clinical significance of UBE2T in primary liver cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 128-133.
[7]	LU Jiaoyun, ZHANG Qingyuan. Advances in laboratory markers in the prognosis of diffuse large B-cell lymphoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 183-187.
[8]	ZHAO Fengjuan, WANG Qi, REN Yunhong, WEI Jueling, LI Lequn, ZHAO Xinhua, TANG Juan, YOU Xuemei. Changes of serum CRP and hs-CRP levels in patients with liver cancer and depression and their influence on prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 27-33.
[9]	ZHANG Fengchun, JIANG Ying, LIU Zhaonan, YAN Ningning, CUI Hongquan, XU Yingchun. Prognostic significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in systemic inflammation-related indicators in gastric cancer patients after radical resection [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 34-39.
[10]	MA Jianli, ZHANG Minghui, JI Hongfei, XU Xiangying. Clinical significance of combined detection of PD-L1 protein and CD8⁺TILs in resected lung adenocarcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 40-46.
[11]	YANG Hongbo, SHI Jie, YE Yong, LI Wencheng, DENG Zhaoping. Expression of COL5A2 in bladder cancer tissues and its correlation with clinicopathological features and prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 52-56.
[12]	WANG Yalong, LYU Zhangyan, ZHANG Fan, FENG Xiaoshuang, WEI Luopei, LI Xin, WEN Yan, GAO Yushun, XUE Qi, GAO Shugeng, TAN Fengwei. Relationship between human papillomavirus infection and prognosis of lung cancer:A meta-analysis [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 520-526.
[13]	TANG Shuli, HE Kuangbang, ZHANG Chunhui, CHENG Jianan, ZHANG Yanqiao. Expression of miR-320a and CYLD in gastric cancer and its relationship with clinicopathological characteristics and prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 538-544.
[14]	XIAO Hongwei, CHEN Sheng, WANG Yanliang, SU Xueliang. The prognostic and influence factors analysis of transanal local resection for stage T₁ rectal cancer with the distance from anal margin ≤8 cm [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 545-549.
[15]	WANG Yiran, HUANG Wei, YIN Lei, LIU Lin, ZHOU Xiaoping, NIU Xingjian, YANG Yue, AN Weiwei, JI Hongfei. The ratio of neutrophil to lymphocyte in the efficacy and prognosis of concurrent chemoradiotherapy in patients with cervical cancer and its clinical significance [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 404-409.

The prognosis predicting effect of serum microRNA in the patients with hepatocellular carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments